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HYPOPHOSPHASTASIA (HPP): PATHOGENESIS AND CURRENT 
TREATMENT OPTIONS 
LUISA LASALLE 
ABSTRACT 
Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease characterized 
by the abnormal development of bones and teeth, due to defective mineralization (1,2). 
HPP is caused by inactivating mutation(s) within the gene that encodes the tissue-
nonspecific isozyme of alkaline phosphatase (TNSALP) (1). These mutations lead to 
impaired bone mineralization leading to various skeletal abnormalities such as rickets and 
fractures, as well as other systemic complications including respiratory manifestations, 
seizures, dental anomalies, pain, and nephrocalcinosis (1–4). Historically, management of 
HPP focused solely on supportive therapy in an attempt to minimize disease-related 
symptoms (1,2). However, in 2015, the Food and Drug Administration (FDA) approved 
Strensiq® (asfotase alfa), an enzyme replacement therapy approved for the treatment of 
patients with perinatal/infantile- and juvenile-onset HPP (3,5). This paper will provide an 
overview of HPP and current and past treatment options for HPP, specially analyzing the 
effectiveness of the newest enzyme-replacement therapy, Strensiq®, which will be more 
effective than previously used therapies in preventing the adverse clinical outcomes of 
HPP.  
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INTRODUCTION 
 Hypophosphatasia, often abbreviated as HPP, is a rare, inherited, metabolic bone 
disease characterized by the abnormal development of bones and teeth, due to defective 
mineralization (1,2). The first published case report of HPP was in Manitoba Canada in 
1936, where two Welsh siblings died of a condition then called “renal rickets,” now 
known to be HPP (1,4). The next case of HPP was reported in 1948. Still, little was 
known about the disease beyond the association with severe rickets, weight loss, and 
seizures (1). Today HPP is understood to be caused by inactivating mutation(s) within the 
ALPL gene that encodes the tissue-nonspecific isozyme of alkaline phosphatase 
(TNSALP) (1). These mutations lead to impaired bone mineralization leading to various 
skeletal abnormalities such as rickets and fractures, as well as other systemic 
complications, including respiratory manifestations, seizures, dental anomalies, pain, and 
nephrocalcinosis (1–4).  
HPP is a rare disease that occurs in approximately 1 in 100,000-300,000 live 
births (4–6). While the disease can impact any patient regardless of background, it is 
more common in specific populations such as the Japanese and the Canadian Mennonite 
community (1). For example, the prevalence of HPP is estimated to be 1 in 100,000 live 
births in Toronto, and as high as 1 in 2,500 for Mennonite families in Manitoba, Canada 
(4). 
The disease can impact patients of all ages, however, the more severe cases are 
seen in utero and infancy, where the mortality rate can be as high as 50% (1). Because 
HPP is a rare disease, it is often misdiagnosed as other skeletal diseases (1,2). It has been 
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suggested that low alkaline phosphatase levels can be a distinguishing feature of HPP 
from other conditions. Historically, management of HPP focused solely on supportive 
therapy in an attempt to minimize disease-related symptoms (1,2). However, in 2015, the 
Food and Drug Administration (FDA) approved Strensiq® (asfotase alfa), an enzyme 
replacement therapy for the treatment of patients with perinatal/infantile- and juvenile-
onset HPP(3,5). Strensiq® was developed by Alexion Pharmaceuticals, and was the first 
drug therapy to address HPP (7). Because the drug has only been approved for under 2 
years, ongoing studies are continuing to research the impact Strensiq® has for patients 
with HPP.  
This paper will provide an overview of hypophosphatasia, including the 
mechanism of disease, clinical presentation of HPP, common signs and symptoms, and 
common misdiagnoses. It will then discuss current and past treatment and management 
options for HPP. Patients with HPP treated with Strensiq®, an enzyme replacement 
therapy, will show improved clinical outcomes, including survival, as compared with 
other HPP treatments. The paper will conclude with a critical analysis of Strensiq® and 
suggestions for future research.  
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MECHANISM OF DISEASE 
 
HPP is caused by inactivating mutations within the ALPL gene that encodes the 
tissue-nonspecific isoenzyme of alkaline phosphatase (TNSALP), leading to overall low 
TNSALP activity (1,2,4). TNSALP plays an essential role in normal skeletal 
development and organ function, primarily through the metabolism of two substrates:  
• Inorganic pyrophosphate (PPi)  
• Pyridoxal 5L phosphate (PLP) 
TNSALP also metabolizes the substrate, phosphoethanolamine (PEA), an 
ethanolamine derivative (1,2,4). However, PEA has no known role in the etiology of 
HPP. In healthy individuals, TNSALP has a significant impact on bone mineralization 
through the precipitation of calcium and inorganic phosphate (Pi) as hydroxyapatite 
crystals in bone matrix vesicles (1,2,4).  
The TNALP substrate PPi consists of two molecules of inorganic phosphate (Pi) 
joined by a hydrolysable high energy ester bond. PPi is an inhibitor of bone 
mineralization. However, normal dephosphorylation of PPi by TNSALP renders it 
inactive and provides a supply of Pi. In patients with HPP, insufficient TNSALP activity 
leads to extracellular accumulation of PPi, which reduces hydroxyapatite formation, 
inhibiting bone mineralization (1,2,4). Further, the accumulation of PPi disrupts bone 
mineralization and impedes normal calcium deposition. Unmineralized bone and the 
associated hypercalcemia results in various skeletal and systemic consequences such as 
non-healing fractures, bone pain, craniosynostosis, hypomineralization of the ribs, and 
abnormal deposition of calcium, particularly in the kidneys (1,2,4). 
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Neurological complications are common in HPP due to the accumulation of another 
TNSALP substrate, PLP. PLP is the principle circulating form of vitamin B6. PLP is 
necessary for normal neurological function, but must be dephosphorylated to pyridoxal 
(PL) by TNSALP in order to cross the blood brain barrier into the central nervous system 
where it is then converted back into PLP (1,2,4). In HPP, low TNSALP activity therefore 
deprives the central nervous system (CNS) of PLP, or Vitamin B6, which impairs the 
synthesis of neurotransmitters and can cause fatal vitamin B6–responsive seizures (1). 
 Overall, the disruption in the function of TNSALP has profound implications for 
the normal formation and mineralization of bone. Figure 1 provides an overview 
illustration of the role of TNSALP in skeletal development in a healthy bone cell and the 
impact of the lack of enzyme in a bone cell with HPP (1,2,4).  
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Figure 1: The role of TNSALP in skeletal development in a healthy bone cell and the 
impact of the lack of TNSALP in a bone cell with HPP. From 
hypophoshatasia.com/hcp.  
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Genetic Basis of Hypophoshatasia  
 More than 300 mutations in the ALPL gene have been identified that are 
associated with HPP. (4). The majority of these are missense mutations, a point mutation 
where a single nucleotide change results in a codon that codes for a different amino acid 
(1). Some deletion, insertion, and splice mutations have been reported, although no large 
deletions or insertions within the actual ALPL gene are known to exist (4). Mutation sites 
have been classified based on the protein regions in which they occur. Mutations that are 
located in the active site of the enzyme, the crown domain, the homodimer interface, and 
the calcium-binding domain are mainly associated with a severe phenotype (Figure 2) 
(4). Mutations that occur in the active site valley generally result in less severe 
phenotypes. Furthermore, the phenotypic severity associated with mutations of specific 
residues depends on the location of mutation at each residue. For example, mutations in 
the C-terminus of the enzyme result in a severe phenotype (4). 
HPP follows either an autosomal recessive or autosomal dominant pattern of 
inheritance, with autosomal recessive HPP typically being more severe. Most patients 
with HPP are transheterozygotes with two different mutant HPP alleles (1,2). 
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Figure 2: The structure and mutation sites of Tissue Nonspecific Alkaline 
Phosphatase. The blue and green ribbons show each monomer. Severe phenotypes 
are associated with mutations located in the active site, the homodimer interface, the 
crown domain, and the calcium-binding domain (4). Figure from Orimo et al., 2016. 
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CLINICAL PRESENTATION 
Clinical Forms 
The clinical presentation of HPP varies in terms of type and severity of the signs 
and symptoms. For example, patients with HPP can be infants with no mineralized bones 
or adults with a high frequency of bone fractures (2). Today, there are six clinical forms 
of HPP recognized, depending on the age at diagnosis. The six clinical forms are listed in 
Table 1.  
Table 1: The clinical forms of hypophosphatasia (2,4) 
Note: perinatal is pertaining to the time around birth, prenatal is regarding before 
birth 
1. Perinatal (lethal)  in utero, at birth, and one 
week after birth 
2. Rare benign prenatal  Before birth, during 
pregnancy 
3. Infantile < 6 months of age 
4. Childhood ≥6 months-18 years of age 
5. Adult ≥ 18 years of age  
6. Odontohypophophatasia  Any age 
 
It is important to note some symptoms occur in more than one clinical subtype. Often 
patients with adult HPP often had clinical symptoms already in childhood when 
reviewing their record. Likewise, infantile and childhood HPP share some clinical 
symptoms, such as fractures and seizures(2).  
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Lethal Perinatal Hypophosphatasia  
In lethal perinatal HPP, patients show impaired bone mineralization in utero (2,4). 
There may also be skin-covered osteochondral spurs protruding from the forearms or 
legs. These spurs are often diagnostic for HPP. Some infants with this form of HPP will 
survive a few days, but often have respiratory complications due to hypoplastic lungs and 
rachitic deformities of the chest. Other symptoms in lethal perinatal HPP are shortening 
of the long bones, apnea, and seizures. Unfortunately, as the name suggests, this form is 
almost always lethal within 7 days of birth (2).  
 
Rare Prenatal Benign Hypophosphatasia 
In this rare form of HPP, prenatal symptoms are present in the fetus but there is 
also spontaneous improvement of skeletal defects. These patients may experience limb 
shortening and bowing in utero. Some ultrasounds reveal progressive improvement of the 
skeletal deformities and mineralization through the third trimester of pregnancy (2,4).  
 
Infantile Hypophoshatasia  
In the infantile form of HPP, patients may appear normal at birth (2,4). However, 
clinical signs of the disease will start to appear during the first six months. A major sign 
of infantile HPP is respiratory complications due to rachitic deformities of the chest. 
Because cranial bones can fuse prematurely in these patients, despite the presence of an 
open fontanelle in radiographs, craniosynotosis is a common finding. Craniosynotosis is 
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when the fibrous sutures in an infant’s skull fuse prematurely through ossification, which 
can result in increased intracranial pressure (2). 
Radiographs in patients with the infantile form of HPP show widespread 
hypomineralization of the skeleton. Hypercalcemia may also be present. This explains in 
part other symptoms experienced by infants with HPP, including failure to thrive, 
dehydration, poor feeding, anorexia, irritability, vomiting, polyuria, and constipation. 
Research has shown that increased excretion of calcium may lead to renal damage in 
these patients (2). Unfortunately, as many as 50% of infants diagnosed with HPP die as a 
consequence of respiratory complications by six months of age (1). 
In patients who survive through infancy, there is often spontaneous improvement 
in mineralization and a remission of most clinical problems. However, neurological 
manifestations such as developmental delays can remain permanent. If these patients 
reach adulthood, they frequently experience short stature and premature loss of their 
deciduous teeth (2).  
 
Childhood Hypophosphatasia 
Clinical presentation of childhood HPP includes skeletal deformities, a delay in 
walking, short stature, a waddling gait, failure to thrive, and signs of increased 
intracranial pressure (1,2,4). Patients will often have a history of fractures and bone pain. 
Focal bony defects near the ends of major long bones may be observed and help point to 
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diagnosis. Premature loss of teeth is also common. Patients’ incisor teeth are usually the 
first to be affected.  
Adult Hypophosphatasia 
Adult HPP often presents during middle age (50-60 years old), but is classified as 
presenting any time after 18 years of age. These patients will often present with foot pain 
due to stress fractures in the metatarsals, and thigh pain due to pseudofractures of the 
femur. Adult HPP can also be characterized by a tendency for chondrocalcinosis, also 
called pseudogout, and marked osteoarthropathy (clubbing of the fingers and toes and 
painful swelling of the joints) later in life. When giving their medical history, many 
patients with adult HPP will reveal that they had premature loss of their deciduous teeth 
(2,4).  
 
Odontohypophosphatasia 
This type of HPP is characterized strictly by premature exfoliation of fully rooted 
primary teeth and/or severe dental cavities. Odontohypophosphatasia is not associated 
with abnormalities of the skeletal system. The anterior deciduous teeth are more likely to 
be affected than other teeth (2,4). Dental x-rays often will show reduced alveolar bone, 
enlarged pulp chambers, and root canals. The only distinguishing clinical feature of this 
type of HPP is dental disease, however biochemical findings in odontohypophosphatasia 
are generally indistinguishable from patients with mild forms of HPP (adult and 
childhood) (2,4). Clinicians believe that odontohypophosphatasia should be considered in 
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any patient with a history of early unexplained loss of teeth or abnormally loose teeth on 
dental examination. Given this information, dentists may be key players in diagnosing 
HPP (2,4).  
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Signs and Symptoms of Hypophosphatasia  
The clinical presentation of HPP varies in terms of type and severity of the signs 
and symptoms. While it is best known as a metabolic bone disease, manifestations are 
systemic and can include skeletal, dental, muscular, rheumatologic, respiratory, 
neurologic, and renal complications (1,4). An overview of the various clinical signs and 
symptoms associated with HPP at different ages of onset can be seen in Table 2.  
 
Table 2: Common signs and symptoms of hypophosphatasia based on age at time 
of diagnosis  (1) 
Perinatal Infantile Childhood Adult 
Stillbirth  
Hypomineralization 
Chest deformity 
Long bone deformity 
Osteochondral spurs 
Poorly ossified 
epiphyses 
Fractures 
Seizures 
Apnea  
 
Fractures 
Rickets 
Pulmonary 
insufficiency 
Failure-to-thrive 
Poor feeding 
Poor weight gain 
Hypotonia 
Seizures 
Nephrocalcinosis 
Hypercalcemia 
Premature 
primary tooth loss 
Craniosynostosis 
Skeletal deformity 
Poorly healing 
and/or recurrent 
fractures 
Low bone mineral 
density 
Short stature 
Muscle weakness 
Missed motor 
milestones 
Chronic pain 
Premature tooth 
loss 
 
Fractures 
Pseudofractures 
Chondrocalcinosis 
Osteomalacia 
Pseudogout 
Chronic pain  
Adult tooth loss 
Abnormal dentition  
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Skeletal  
Skeletal manifestations of HPP are the most common and well known, leading to 
devastating systemic manifestations (Table 3). Death in infants with HPP who present 
before 6 months of age usually occurs as a result of severe skeletal hypomineralization 
(1). This hypomineralization leads to hypoplastic lungs, chest deformities, progressive 
demineralization, and pulmonary insufficiency and respiratory failure. In surviving 
infants and children with HPP, rachitic chest and hypomineralization are two hallmarks 
of the disease. These patients often experience reparatory difficulty and require 
ventilation support due to a small, rachitic thorax (1).  
Skeletal manifestations may vary depending on the age at which a patient is 
diagnosed with HPP. In severely affected infants at delivery, limbs may be shorted and 
deformed. In addition, osteochondral spurs which protrude from the ulna or fibula, and 
pierce the skin may be present. In older children (over 7 years of age) skeletal finding 
may include bowed legs or knock knees, the enlargement of the wrists, knees, and ankles 
(from flared metaphyses), and occasionally brachycephalic skulls (1,2). These patients 
may also report bone pain and join discomfort, especially stiffness and swelling. In older 
adult patients (over 50 years of age) the most common skeletal manifestations are 
multiple fractures, especially metatarsal stress fractures. These patients may also 
experience pseudo-fractures as a result of poorly healing fractures. These can require 
surgical interventions and cause disability and severe chronic pain (1,2). 
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Radiographic evidence of HPP is essential in diagnosing and treating HPP. 
Characteristic radiographic abnormalities in patients with HPP are long-bone bowing, 
shortened long bones, and osteochondral spurs. Other less common radiographic 
evidence may include physeal widening, metaphyseal flaring, and an irregularity of the 
zone of calcification. X-ray findings such as pseudofracture, pseudogaout, and 
chondrocalcinosis may also be present in some HPP patients. (1,2). 
Table 3: Skeletal manifestations in patients with hypophosphatasia (1,2,6,8). 
• Severe hypomineralization 
• Progressive skeletal demineralization 
• Hypophosphatasia-induced rickets 
• Bowing 
• Skeletal deformities 
• Bone pain 
• Osteomalacia 
• Frequent, nonhealing, nontraumatic, or recurrent fractures 
• Short stature 
• Multiple surgical interventions 
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Systemic Manifestations 
 In addition to the serious skeletal consequences of HPP, the deficiency in 
TNSALP and the accumulation of its substrates are also associated with consequences 
impacting the respiratory, neurologic, renal, muscular, and dental systems.  
Respiratory Manifestations 
 Most respiratory manifestations in patients with HPP are consequences of skeletal 
signs and symptoms related to hypomineralization. This hypomineralization leads to 
hypoplastic lungs, chest deformities, progressive demineralization, and pulmonary 
insufficiency and respiratory failure. Younger patients often experience respiratory 
difficulty and require ventilation support due to a small, rachitic thorax (1,2). 
 
Figure 3:  Rachitic chest in pediatric patient with hypophosphatasia. From 
Rockman-Greenberg 2013 (1). 
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Neurologic Manifestations 
A major, and perhaps one of the most devastating neurologic manifestations of 
HPP, is seizures. The most severe complications due to seizures occur in newborns with 
HPP, as a result of extracellular elevation of the substrate PLP, and the resulting 
deficiency in the central nervous system of PL. (1,2). Sometimes newborns will 
experience seizures before the skeletal disease is obvious. 
Craniosynostosis is another harmful neurologic manifestation of HPP. In infants 
with HPP, there can be an early fusion of the cranial sutures due to soft tissue synostosis. 
In the perinatal period, membranous bones may calcify and give the impression of being 
separated when in fact they are actually closed. This can lead to increased intracranial 
pressure and papilledema, and may require surgical treatment. Craniosynostosis can also 
lead to intracranial hemorrhage, optic nerve damage, and the need for multiple cranial 
surgeries (1,2).  
 
Renal Manifestations 
Some patients with HPP can experience initial skeletal manifestations that 
actually appear less severe than the biochemical, and other systemic abnormalities, such 
as renal manifestations (1,2). The reduction in TNSALP leading to defective bone 
mineralization and impaired regulation of phosphate and calcium can result in these renal 
consequences. Patients with HPP may experience hypercalcemia (high calcium levels in 
the blood), hypercalciuria (elevated calcium in the urine), and hyperphosphatemia (high 
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phosphate levels in the blood). Elevated calcium can result in nephrocalcinosis and renal 
damage (1,2).  
 
Muscular and Rheumatologic Manifestations 
Patients with HPP can experience mobility-related muscular and rheumatologic 
manifestations that can impact their daily lives. A common muscular manifestation 
among patients with HPP is muscle weakness. The exact cause of muscular symptoms 
associated with HPP is not understood but is postulated to be due to elevated 
pyrophosphate that may inhibit muscle function (1,2). Nevertheless, defective bone 
mineralization and impaired regulation of phosphate and calcium may lead to a range of 
consequences including muscle and joint pain, joint stiffness and swelling, and 
hypotonia. Children with HPP may have a characteristic waddling gait and delayed 
walking as compared to their healthy peers (1,2).  
Because of the disturbance of normal calcium and phosphate metabolism, some 
patients with HPP may experience calcium pyrophosphate dehydrate (CPPD) deposition 
which may lead to pseudogout and/or calcific periathritis. This is more common in adults 
with HPP. Also, chondrocalcinosis may be visualized on X-ray in these patients (1,2).  
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Dental Manifestations 
 A history of issues with dentition is frequently reported in patients with HPP, 
especially children, adolescents, and adults. The most common dental manifestation is the 
premature loss of deciduous (also known as primary or baby) teeth, sometimes with the 
entire root intact. Some patients will experience exfoliation of their teeth without 
absorption of the root. This is often accompanied by a reduction in the alveolar bone 
height and hypoplasia of the cementum. These dental symptoms can be early indicators 
of HPP. A study found that a deficiency in TNSALP not only affects the mineralization 
of bones and teeth, but also the mineralization of acellular cementum deposition of the 
root surfaces of teeth (1). Research suggests that tooth development may be the most 
sensitive developmental process that is dependent on TNSALP function. When patients 
are diagnosed with HPP, especially adolescent or adult patients, a history may reveal that 
they experienced early loss of teeth or had a history of early loss or extraction of adult 
teeth (1). As discussed previously, if tooth loss is the only finding, it is referred to as 
odontohypophosphatasia. 
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Common Misdiagnoses of Hypophosphatasia 
 Like many rare diseases, HPP is often misdiagnosed because its clinical 
presentation can be similar with the signs and symptoms of other disorders (1,2). Some 
common misdiagnoses that patients with HPP may receive can be seen in Table 4.  
Table 4: Common misdiagnoses of hypophosphatasia (9–14) 
Osteogenesis imperfecta  A genetic disorder characterized by reductions in 
type I collagen, which causes bones to be brittle 
and fracture easily from mild trauma or no 
apparent cause (9).  
Osteomalacia Caused by severe vitamin D deficiency, 
osteomalacia is characterized by softening of the 
bones. Children and young adults can have 
bowing, especially in the weight-bearing bones of 
the legs (10). 
Osteopenia A bone condition characterized by a decreased 
density of bone. This can lead to bone weakening 
and an increased risk of fractures. This decreased 
bone density is not to the extent of osteoporosis 
(11).  
Osteoporosis A condition characterized by a decrease in bone 
density. This leads to abnormally porous bones that 
are compressible, resulting in very weak and 
fragile bones (12). 
Nutritional rickets Often caused by vitamin D deficiency, nutritional 
rickets are characterized by the failure of osteoid to 
calcify in children (15).  
X-linked hypophosphatemia An inherited disorder characterized by low 
phosphate levels in the blood due to abnormally 
processed phosphate in the kidneys. Low 
phosphate levels lead to soft and weak bones (14).  
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Diagnosing Hypophosphatasia With a Blood Test  
Today, it is easy to avoid a misdiagnosing HPP by testing TSALP levels through 
a blood test. Low levels of TSALP is characteristic of HPP and can help differentiate it 
from other metabolic disorders that can present similarly (Table 5) (1,2,16).  
 
Table 5: TNSALP Lab Values Can Help Differentiate HPP From Other Disorders 
 
HPP 
 
Nutritional rickets 
 
X-linked 
hypophosphatemia 
 
Osteogenesis 
imperfecta 
 
Low TSALP (16) 
 
High TSALP (13) 
 
High TSALP (17) 
 
Normal TSALP (16) 
 
 It is important to note that failure to correctly diagnose HPP can actually lead to 
compounding clinical consequences. For example, treatments for other common 
misdiagnoses such as high dose vitamin D, calcium supplements, and bisphosphonates 
have been shown to exacerbate the symptoms of HPP (1,2,16).  
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TREATING HYPOPHOSPHATASIA 
 In 2015, the Food and Drug Administration (FDA) approved Strensiq® (asfotase 
alfa), an enzyme replacement therapy approved in the United States for the treatment of 
patients with perinatal/infantile- and juvenile-onset HPP. Figure 4 shows the structure of 
the glycoprotein, asfotase alfa, which is composed of a soluble form of tissue-nonspecific 
alkaline phosphatase, the Fc region of human IgG, and deca-aspartate (4).  
 
 
 
Figure 4: The structure of asfotase alfa. The peptide part of the glycoprotein 
consists of two identical chains of 726 amino acids, containing the catalytic domain 
of TNSALP, the FC region of human IgG, and a sequence of ten L-aspartate 
residues. The two chains are linked by two disulfide (4). Figure from Orimo et al., 
2016.  
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Strensiq® was developed by Enobia Pharmaceuticals, which was later acquired by 
Alexion Pharmaeuticals. It was the first approved drug therapy to treat HPP. However, 
before Strensiq® was approved by the FDA, management of HPP focused solely on 
supportive therapy in an attempt to minimize disease-related symptoms.  
 
The History of Managing and Treating Symptoms of HPP 
Many clinical trials evaluating treatments for HPP have been carried out, 
however, many have failed. Before enzyme-replacement therapies (ERTs), management 
of HPP focused solely on supportive therapy in an attempt to minimize disease-related 
symptoms. These therapies included giving patients vitamin B6 to for those affected with 
seizures, surgery to repair fractures, surgery to relieve intracranial pressure, pain 
management such as nonsteroidal anti-inflammatory drugs (NSAIDs), and dental care 
(1,4). In addition, to address respiratory failure, artificial respiration is often used. (1,4).  
Various ERTs have been attempted to treat HPP. Studies found that three female 
patients who had the mild form of HPP were found their HPP-related symptoms to 
actually improve when they were pregnant because of the increased activity of placental 
alkaline phosphatase (PLAP) (18). There was an immediate postpartum drop of PLAP 
levels within four days of giving birth, and HPP-related symptoms did come back (18). 
However, because of the observation of the reduced symptoms with increased PLAP, a 
case report of infusion of PLAP into an infant with severe HPP was attempted, however, 
no improvement was observed (18).  
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Clinical Trials with Asfotase Alfa 
Asfotase alfa, the chemical name for Strensiq ® was initially tested in a mouse 
model. Mice with a mutation in Alpl (TNALP-null mice (Akp2−/−)) were created and 
confirmed as a suitable model of HPP (4). The mice showed hypomineralization of the 
bone, rickets, osteomalacia, failure to thrive, seizure, and abnormal dental manifestations 
(4). The mice mimicked the manifestations of severe HPP patients, however one major 
difference between them was the presence of epileptic seizures in almost all of the mice, 
a complication rarely seen in patients with HPP (4). 
In 2008, the first successful treatment of Alpl-null mice with bioengineered 
human TNSALP was reported (19). For this study, Human TNALP was bioengineered 
with the C terminus extended by the Fc region of human IgG for one-step purification 
and a deca-aspartate sequence (D10) (19). The mice were treated from birth with once 
daily subcutaneous injections of three different doses for various lengths of time (19). 
Specifically, short-term and long-term efficacy studies consisted of once daily 
subcutaneous injections of 1, 2, or 8.2 mg/kg of asfotase alfa for 15, 19, and 15 or 52 
days, respectively (19). Endpoints assessed were survival and growth rates, circulating 
levels of asfotase alfa, calcium, PPi, and pyridoxal, as well as skeletal and dental 
manifestations using radiographic evidence (19). 
Results found that the mice receiving the high dose of human TNSALP grew 
normally and appeared to have no skeletal or dental symptoms. Radiographic evidence 
showed improvements and levels of plasma calcium, PPi, and pyridoxal remained in their 
normal ranges for treated mice. These results lead researchers to conclude that this 
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enzyme replacement therapy using a recombinant form of human TNSALP can prevent 
infantile HPP in TNSALP-null mice (19). 
Given the hopeful results of this study, a clinical trial was conducted by Dr. 
Whyte in the United States and the first results were reported in 2012 (20). The study 
enrolled eleven infants and young children with life-threatening or infantile HPP in a 
multinational, open-label study of treatment with asfotase alfa, the same TNSALP that 
was used in previous studies using a mouse model (20). In this study asfotase alfa was 
referred to as ENB-0040. In this study, the primary outcome that was evaluated as a 
measure of efficacy was the healing of rickets which was assessed through radiographic 
scales (21). Specifically, researchers used the Radiographic Global Impression of Change 
(RGI-C) score, a 7-point ordinal scale which assesses hypophosphatasia skeletal disease 
in wrists and knees, including physeal widening, irregularity of the provisional zone of 
calcification, metaphyseal flaring, radiolucencies, as well as recent fractures  (21). 
Other outcomes measured were motor and cognitive development and respiratory 
function  (21). Each patient was treated with 2 mg/kg of ENB-0040 (asfotase alfa; 40 
mg/mL) provided by Enobia Pharma, Inc. (as a single intravenous infusion followed by 
subcutaneous injections three times per week at a dose of 1 mg/kg for 48 weeks. 
Of the eleven patients that were recruited, ten completed six months of therapy, 
and nine completed one year(21). With the exception of one subject who died of 
respiratory failure that was unrelated to asfotase alfa, the recruited patients showed 
measurable improvements. Nine patients saw healing of rickets based on the RGI-C scale 
after 6 months of treatment as well as improvements in developmental milestones and 
	26 
pulmonary function (21). Additional significant improvements included patient growth, 
strength, motor function, agility, and quality of life, which reached normal values for 
their healthy peers was sustained for the full 5 years of treatment  (21). 
Substrates PLP and PPi, which were initially elevated in all patients at baseline, 
lowered after treatment. For PLP, levels were at 262 ng per milliliter (1060 nM) at 
baseline, 46 ng per milliliter (186 nM) at 24 weeks, and 23 ng per milliliter (93 nM) at 48 
weeks (21). Similarily, plasma levels of PPi were measured before and after treatment in 
five of the patients, and the median level decreased from 5.2nM at baseline to 1.1nM at 
week 24 (21).  
This was breakthrough clinical trials for patients with HPP. However, like any 
study had some limitations, including the fact that the sample size was so low 
(unavoidable with rare diseases), and that because it’s a newer study, there is not 
currently follow up data or any data to assess what happens when patients stop taking the 
therapy.  
Other studies looked at the effects of asfotase alfa in young children with HPP. A 
study from 2012 followed the efficacy of therapy for juvenile patients. Researchers 
evaluated the efficacy and safety of asfotase alfa treatment administered to children 6-12 
years of age who were substantially impaired by HPP at baseline (childhood form) (20). 
Using the same radiographic scale, skeletal disease from HPP was quantified. Twelve 
children received the treatment and were studied for five years. Patients received 
injections of asfotase alfa in a low or high dose (40 or 100 mg/ml concentration) for 3 
mg/kg three times a week (20).  
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The primary outcome in this study was also evaluation of changes in the skeletal 
manifestations using the RGI-C scale. Results found that after six months of treatment, 
significant radiographic improvements were observed using this scale (20). Other 
improvements were seen in the children including improved patient growth, strength, 
agility, and overall quality of life (20).  
Levels of ALP, PLP, and PPi all reached normal levels after threaten. The 
medium level of ALP activity in the treatment group at baseline was 49IU/I and rapidly 
increased with treatment, and was still elevated at the 5 years of therapy point with a 
median level of 5747 IU/l (20). Elevated plasma levels of the TNSALP substrates PPi 
and PLP decreased in subjects. Specifically, the median concentration of baseline PPi 
concentration was 4.9 µM (3.7, 7.0), which at the upper limit of the age-dependent 
reference range (0.75–5.71 µM).The baseline PLP median concentration was 218 ng/ml 
(76, 527), which is much higher than the normal range (normal 5.7–61.2 ng/ml) (20). At 
the 6 weeks of treatment period, the was a rapid and significant reduction in both the 
plasma PPi and PLP concentrations for most of the treated patients (2.0 µM [1.3, 3.1] and 
10.6 ng/ml [0.9, 40.3], respectively) (20). These normal values persisted throughout the 
study (20). 
The study concluded that this enzyme replacement therapy had substantial and 
sustained efficacy with a good safety profile for children suffering from HPP (20). In 
both studies (infantile HPP and childhood HPP), the most common adverse event was 
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mild to moderate injection-site reactions which were sometimes associated with 
lipohypertrophy (20). Anti–asfotase alfa antibody titers were noted in all patients. 
In a review of two clinical trials of asfotase alfa, researchers documented the 
survival data for patients with perinatal and infantile HPP, as compared to historical 
controls.  Data was collected from patients with the perinatal and infantile forms of HPP 
in two ongoing, multicenter, multinational, open-label, phase 2 interventional studies of 
asfotase alfa treatment (8). Historical control data was obtained from a retrospective 
natural history study. At the time of this review, patients had only been treated for 48 
weeks, but researchers found that treatment improved overall survival to 97% at 48 
weeks in these patients, as seen in Figure 5 (8). 
 
Figure 5: Kaplan-Meier analysis of survival of patients with perinatal and infantile 
HPP. Patients treated had better overall survival as compared with historical 
controls. From Whyte 2016 (8). 
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 It was these studies that led to approval of asfotase alfa, also known as Strensiq®. 
Strensiq® in July 2015 in Japan, followed by approval in the European Union and 
Canada in August and then by the FDA in October 2015. 
In the U.S., Strensiq® is indicated for the treatment of patients with 
perinatal/infantile- and juvenile-onsent HPP (22). In simple terms, and according to the 
Strensiq® website, “by replacing alkaline phosphatase (ALP), Strensiq® improved bone 
mineralization, growth, survival, and movement” (22).  
 
CONCLUSION 
Hypophosphatasia (HPP) is a rare, inherited, metabolic bone disease characterized 
by the abnormal development of bones and teeth, due to defective mineralization (1,2). 
HPP is caused by inactivating mutation(s) within the ALPL gene that encodes TNSALP 
(1). These mutations lead to impaired bone mineralization leading to various skeletal 
abnormalities, as well as other systemic complications including respiratory 
manifestations, seizures, dental anomalies, pain, and nephrocalcinosis (1–4). Historically, 
management of HPP focused solely on supportive therapy in an attempt to minimize 
disease-related symptoms (1,2). However, FDA approval of Strensiq® (asfotase alfa), the 
first enzyme replacement therapy approved for the treatment of patients with 
perinatal/infantile- and juvenile-onset HPP greatly changed how HPP was treated (3,5).  
There is no question that Strensiq® is a life-changing therapy for patients with 
HPP, as the development of this drug has improved and saved lives. However, 
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improvements to the therapy as well as further research on the pathogenesis of the disease 
is necessary.  
 The subjects enrolled in the clinical trials that have been carried out so far for 
Strensiq® were patients diagnosed with the perinatal, infantile, and juvenile forms of 
HPP. For the milder forms, such as adult and odontohypophosphatasia, the safety and 
efficacy have not yet been established. Therefore, future research with Strensiq® should 
focus on these clinical types. The adult form of the disease is not well understood, so 
research should also address the natural history of the adult form so treatments can be 
adapted for these patients (4). Also, more studied should be conducted on patients with 
the perinatal, infantile, and juvenile forms of HPP, since the number of patients in these 
studies were small. All studies should have longer-follow up periods, as patients taking 
Strenisq® will need to be on the treatment for the rest of their lives, and it is unclear what 
the long-term effects will be.  
 One of the main concerns for patients taking Strenisq® is the method of 
administration. Because it is a subcutaneous injection that must be administered at least 
three times per week, it has become a big burden for patients, especially pediatric patients 
(4). Also, Strensiq a weight-based dose therapy, which means the dose patients need 
increases as they age and grow larger. This increase in dose can put a financial strain on 
patients.  
 Alexion Pharmaceuticals, the maker of Strensiq®, has faced criticism for the price 
of the drug. The cost for Strensiq® solution (of 18mg/0.45mL) is around $15,793 for a 
supply of 5.4 milliliters (23), which can cost  $200,000 to $300,000 per patient per year 
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(24). Insurance coverage for the drug varies by different plans. However, what does not 
vary is the financial burden that this drug will likely cause families who have members 
with HPP. While most drug companies won’t develop drugs for rare and orphan 
conditions, because the patient population is so small, those who do have faced similar 
criticism as this industry becomes a new niche for pharma to occupy. A balance must be 
reached between innovation for pharmaceutical companies to develop orphan drugs and 
affordability and accessibility for those patients with these rare and orphan conditions.   
 In conclusion, the data from the clinical trials supports the hypothesis that 
Strensiq® is currently the best therapy for patients with HPP, as it improves clinical 
outcomes, including survival, compared to other HPP treatments. While future research 
should expand its study groups and continue to study the long-term effects of Strensiq®, it 
is the best treatment option, especially compared to the various ways HPP has been 
managed in the past.  
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